北京华世天富

Beijing Huashi Tianfu Biotechnology is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of next-generation immune cell therapies for solid tumors. The company leverages its proprietary T-Max cell expansion platform to improve the fitness, persistence, and anti-tumor activity of CAR-T, TCR-T, and TIL products. Its lead candidates, HS-T001 and HS-T002, are currently in clinical development targeting Mesothelin and Glypican-3, respectively, for high-unmet-need cancers such as pancreatic and liver cancer. Huashi Tianfu aims to overcome the immunosuppressive challenges of the tumor microenvironment through innovative cell engineering and optimized manufacturing processes. The company operates a dedicated GMP manufacturing facility to support its clinical pipeline and future commercialization efforts.